These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 34305920)

  • 1. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
    Zhou X; Du J; Liu C; Zeng H; Chen Y; Liu L; Wu D
    Front Immunol; 2021; 12():688215. PubMed ID: 34305920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pan-cancer analysis of RNASEH1, a potential regulator of the tumor microenvironment.
    Yi C; Yang J; Zhang T; Xie S; Li W; Qin L; Chen D
    Clin Transl Oncol; 2023 Aug; 25(8):2569-2586. PubMed ID: 37022517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples.
    Di W; Fan W; Wu F; Shi Z; Wang Z; Yu M; Zhai Y; Chang Y; Pan C; Li G; Kahlert UD; Zhang W
    Cancer Sci; 2022 Feb; 113(2):756-769. PubMed ID: 34881489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis.
    Mathewson ND; Ashenberg O; Tirosh I; Gritsch S; Perez EM; Marx S; Jerby-Arnon L; Chanoch-Myers R; Hara T; Richman AR; Ito Y; Pyrdol J; Friedrich M; Schumann K; Poitras MJ; Gokhale PC; Gonzalez Castro LN; Shore ME; Hebert CM; Shaw B; Cahill HL; Drummond M; Zhang W; Olawoyin O; Wakimoto H; Rozenblatt-Rosen O; Brastianos PK; Liu XS; Jones PS; Cahill DP; Frosch MP; Louis DN; Freeman GJ; Ligon KL; Marson A; Chiocca EA; Reardon DA; Regev A; Suvà ML; Wucherpfennig KW
    Cell; 2021 Mar; 184(5):1281-1298.e26. PubMed ID: 33592174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
    Qiu P; Guo Q; Yao Q; Chen J; Lin J
    Front Immunol; 2021; 12():736030. PubMed ID: 34659224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
    Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Pan-Cancer Analysis of KLRB1 with Prognostic Value and Immunological Activity across Human Tumors.
    Cheng X; Cao Y; Wang X; Cheng L; Liu Y; Lei J; Peng W; Shi D
    J Immunol Res; 2022; 2022():5254911. PubMed ID: 35028320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD161, a promising Immune Checkpoint, correlates with Patient Prognosis: A Pan-cancer Analysis.
    Ye W; Luo C; Li C; Liu Z; Liu F
    J Cancer; 2021; 12(21):6588-6599. PubMed ID: 34659549
    [No Abstract]   [Full Text] [Related]  

  • 10. PNOC Expressed by B Cells in Cholangiocarcinoma Was Survival Related and LAIR2 Could Be a T Cell Exhaustion Biomarker in Tumor Microenvironment: Characterization of Immune Microenvironment Combining Single-Cell and Bulk Sequencing Technology.
    Chen Z; Yu M; Yan J; Guo L; Zhang B; Liu S; Lei J; Zhang W; Zhou B; Gao J; Yang Z; Li X; Zhou J; Fan J; Ye Q; Li H; Xu Y; Xiao Y
    Front Immunol; 2021; 12():647209. PubMed ID: 33841428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High gene expression of estrogen and progesterone receptors is associated with decreased t cell infiltration in patients with NSCLC.
    Oh MS; Anker JF; Chae YK
    Cancer Treat Res Commun; 2021; 27():100317. PubMed ID: 33711637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analyses of the heterogeneity and prognostic significance of tumor-infiltrating immune cells in non-small-cell lung cancer: Development and validation of an individualized prognostic model.
    Pang Z; Chen X; Wang Y; Wang Y; Yan T; Wan J; Du J
    Int Immunopharmacol; 2020 Sep; 86():106744. PubMed ID: 32623229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers.
    Xu HH; Gan J; Xu DP; Li L; Yan WH
    Front Immunol; 2021; 12():614773. PubMed ID: 34276642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of an immune-related gene signature for prediction of prognosis in patients with cervical cancer.
    Mei J; Xing Y; Lv J; Gu D; Pan J; Zhang Y; Liu J
    Int Immunopharmacol; 2020 Nov; 88():106882. PubMed ID: 32799114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of LOXL3-associating immune infiltration landscape and prognostic value in hepatocellular carcinoma.
    Wang N; Zhou X; Tang F; Wang X; Zhu X
    Virchows Arch; 2021 Dec; 479(6):1153-1165. PubMed ID: 34448895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CMTM3 as a Potential New Immune Checkpoint Regulator.
    Shen Q; Cong Z; Zhou Y; Teng Y; Gao J; Tang W
    J Oncol; 2022; 2022():2103515. PubMed ID: 36245970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer.
    Liu B; Fu T; He P; Du C; Xu K
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34143198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data.
    Liu Q; Cheng R; Kong X; Wang Z; Fang Y; Wang J
    Front Immunol; 2020; 11():558757. PubMed ID: 33329517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer.
    Hu Q; Nonaka K; Wakiyama H; Miyashita Y; Fujimoto Y; Jogo T; Hokonohara K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Masuda T; Oki E; Mimori K; Oda Y; Mori M
    Cancer Med; 2021 May; 10(9):3129-3138. PubMed ID: 33769705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.